Skip to content
Home/Companies/Pharma/Deallus

Deallus

Pharma·United Kingdom·Exited 2024·Held 9yr
Entry
2015
Hold
9yr
Exit
2024

Who owns Deallus?

Deallus is a British Pharma company, now owned by GlobalData, which acquired it in 2024 from ARCHIMED.

Hand-verified · updated 2026-09-30

Open JSON · CC-BY
ARCHIMED
Investor
ARCHIMED
MED I · 2014 · Buyout

Key facts

HQUnited Kingdom
SectorPharma
Exit Type
Trade Sale
Buyer
GlobalData Plc
Exit Year
2024

More from MED I

Other portfolio companies in the same fund.

Stago
Stago
Active
MedTechFrance· 2026
Fytexia
4.0xExited 2023
HealthTechFrance· 2016
to Associated British Foods
Micromed
Micromed
Exited 2023
MedTechFrance· 2016
to Natus Medical (ARCHIMED portfolio company, intra-portfolio)
Natural Origins
Natural Origins
2.5xExited 2017
HealthTechFrance· 2016
to Dohler Group
Polyplus
Polyplus
300.0xExited 2023
BiotechFrance· 2016
to Sartorius Stedim
Primo Group
Primo Group
3.0xExited 2024
HealthTechItaly· 2015
to Aksia

More PE-backed in Pharma

Comparable pharma deals from other GPs.

Abacus Pharmaceuticals
Abacus Pharmaceuticals
Active
The Carlyle GroupUS
AdipoPharma
AdipoPharma
Active
Capital Grand EstFrance
Advantice Health
Advantice Health
Active
TA AssociatesUS
Alcala Farma
Active
Advent InternationalSpain
Alvogen
Alvogen
Active
CVC Capital Partners
Anovo
Anovo
Active
ArdianUS

Questions

Who owns Deallus?

Deallus is now owned by GlobalData, which acquired it in 2024 from ARCHIMED.

When did GlobalData acquire Deallus?

GlobalData acquired Deallus in 2024, buying from ARCHIMED.

Who did Deallus sell to?

ARCHIMED sold Deallus to GlobalData in 2024 (Trade Sale).

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue